These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

996 related items for PubMed ID: 32958451

  • 21. Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial.
    de Feria Cardet RE, Hofman MS, Segard T, Yim J, Williams S, Francis RJ, Frydenberg M, Lawrentschuk N, Murphy DG, De Abreu Lourenco R.
    Eur Urol; 2021 Mar; 79(3):413-418. PubMed ID: 33341285
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Diagnostic Performance of 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography to Monitor Treatment Response in Patients with Metastatic Prostate Cancer: The Concordance Between Biochemical Response and Prostate-specific Membrane Antigen Results.
    Esen B, Seymen H, Tarim K, Koseoglu E, Bolukbasi Y, Falay O, Selçukbiricik F, Molinas Mandel N, Kordan Y, Demirkol MO, Tilki D, Esen T.
    Eur Urol Focus; 2023 Sep; 9(5):832-837. PubMed ID: 37032281
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate Cancer Trial (PASPoRT).
    Heetman JG, Lavalaye J, Polm PD, Soeterik TFW, Wever L, Paulino Pereira LJ, van der Hoeven EJRJ, van Melick HHE, van den Bergh RCN.
    Eur Urol Oncol; 2024 Apr; 7(2):204-210. PubMed ID: 37296065
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre.
    Haran C, McBean R, Parsons R, Wong D.
    J Med Imaging Radiat Oncol; 2019 Aug; 63(4):495-499. PubMed ID: 30972933
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [68Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer.
    Hirmas N, Al-Ibraheem A, Herrmann K, Alsharif A, Muhsin H, Khader J, Al-Daghmin A, Salah S.
    Mol Imaging Biol; 2019 Jun; 21(3):574-581. PubMed ID: 30215174
    [Abstract] [Full Text] [Related]

  • 33. Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study.
    Donswijk ML, van Leeuwen PJ, Vegt E, Cheung Z, Heijmink SWTPJ, van der Poel HG, Stokkel MPM.
    BMC Cancer; 2020 Aug 05; 20(1):723. PubMed ID: 32758168
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
    van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, Stricker PD.
    BJU Int; 2017 Feb 05; 119(2):209-215. PubMed ID: 27207581
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Importance of magnetic resonance imaging and prostate-specific membrane antigen PET-CT in patients treated with salvage radical prostatectomy for radiorecurrent prostate cancer.
    Rajwa P, Pfister D, Rieger C, Heidenreich J, Drzezga A, Persigehl T, Shariat SF, Heidenreich A.
    Prostate; 2023 Mar 05; 83(4):385-391. PubMed ID: 36564936
    [Abstract] [Full Text] [Related]

  • 38. Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial.
    Jansen BHE, Bodar YJL, Zwezerijnen GJC, Meijer D, van der Voorn JP, Nieuwenhuijzen JA, Wondergem M, Roeleveld TA, Boellaard R, Hoekstra OS, van Moorselaar RJA, Oprea-Lager DE, Vis AN.
    Eur J Nucl Med Mol Imaging; 2021 Feb 05; 48(2):509-520. PubMed ID: 32789599
    [Abstract] [Full Text] [Related]

  • 39. 68Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer.
    Klingenberg S, Jochumsen MR, Ulhøi BP, Fredsøe J, Sørensen KD, Borre M, Bouchelouche K.
    J Nucl Med; 2021 Feb 05; 62(2):214-220. PubMed ID: 32444374
    [Abstract] [Full Text] [Related]

  • 40. Impact of Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography on the Therapeutic Decision of Prostate Carcinoma Primary Staging: A Retrospective Analysis at the Brazilian National Public Health System.
    da Silva ACB, de Toledo LGM, de Carvalho Fernandes R, Ziroldo AR, Sawczyn GV, Alarcon ST, Lewin F.
    Ann Surg Oncol; 2023 Jul 05; 30(7):4541-4549. PubMed ID: 36995451
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 50.